Despite the compelling evidence for greater toxicity in female patients, sex-specific anticancer treatment strategies are missing. Increased awareness of sex differences at all stages of drug development by researchers, the pharmaceutical industry, funding institutions and regulatory agencies is needed to accurately implement precision oncology.
References
Unger, J. M. et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J. Clin. Oncol. 40, 1474–1486 (2022).
Zucker, I. & Prendergast, B. J. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex Differ. 11, 32 (2020).
Wagner, A. D. et al. Gender medicine and oncology: report and consensus of an ESMO Workshop. Ann. Oncol. 30, 1914–1928 (2019).
Hopkins, J. J. & Sawyer, M. B. Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments. Cancer Chemother. Pharmacol. 82, 1–29 (2018).
Trinkner, P. et al. Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis. Eur. J. Cancer 184, 151–171 (2023).
Wagner, A. D. et al. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database. J. Clin. Oncol. 38, 4029–4029 (2020).
Ye, Y. et al. Sex-associated molecular differences for cancer immunotherapy. Nat. Commun. 11, 1779 (2020).
Shah, M., Rahman, A., Theoret, M. R. & Pazdur, R. The drug-dosing conundrum in oncology — when less is more. N. Eng. J. Med. 385, 1445–1447 (2021).
Jenei, K., Meyers, D. E. & Prasad, V. The inclusion of women in global oncology drug trials over the past 20 years. JAMA Oncol. 7, 1569–1570 (2021).
Jenei, K., Raymakers, A., Meyers, D. E. & Prasad, V. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015–2020. J. Cancer Policy 30, 100311 (2021).
Özdemir, B. C., Richters, A., Espinosa da Silva, C. & Berner, A. M. Cancer researchers’ perceptions of the importance of the sex of cell lines, animals, and human samples for cancer biology research. iScience 26, 106212 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares receiving honoraria paid to her institution for lectures and advisory boards from BMS, MSD, Merck, Ipsen, Roche, Pfizer, Novartis, Janssen and Sanofi.
Rights and permissions
About this article
Cite this article
Özdemir, B.C. Removing barriers to address sex differences in anticancer drug toxicity. Nat Rev Cancer 24, 161–162 (2024). https://doi.org/10.1038/s41568-023-00651-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-023-00651-w
- Springer Nature Limited